NCT05798143: ReModula

Translational Biomarkers in Accelerated Neuromodulation for Treatment-resistant Depression

Recruiting now NA Last updated 4 April 2023

What this trial tests

NA trial testing Accelerated Repetitive Transcranial Magnetic Stimulation in Treatment Resistant Depression in 80 participants. Currently enrolling.

Timeline

28 February 2023

Primary endpoint
31 December 2026

31 December 2028

Quick facts

Lead sponsor	ITAB - Institute for Advanced Biomedical Technologies
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	28 February 2023
Primary completion	31 December 2026
Estimated completion	31 December 2028
Sites	1 location across Italy

Drugs / interventions tested

• Accelerated Repetitive Transcranial Magnetic Stimulation

Conditions studied

• Treatment Resistant Depression — all drugs for Treatment Resistant Depression →

Sponsor

ITAB - Institute for Advanced Biomedical Technologies

Who can join

Adults 18 to 65, any sex, with Treatment Resistant Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: 30-50% of patients with Major Depressive Disorder (MDD) do not respond adequately despite two or more antidepressant treatments with proper dosage and timing of administration, configuring a condition of Treatment-Resistant Depression (TRD). Repetitive Transcranial Magnetic Stimulation (rTMS) is a neuromodulation technique that uses a magnetic field to stimulate focal cortical brain regions and it has been approved by the FDA for the treatment of TRD. Accelerated rTMS (arTMS) protocols involve multiple daily sessions of rTMS and they have been shown to be equally effective and safe compared to rTMS protocols, with reduced administration time and potentially faster antidepressant efficacy.

Objectives: The main aim of this study is to identify MDD endophenotypes/biotypes predictive of response to accelerated treatment of rTMS to better characterize the clinical correlates of response in patients with TRD.

Eligibility: Subjects between 18 and 65 years suffering from TRD in stable psychopharmacological treatment for at least one month.

Design: This clinical trial includes three phases: 1) a screening phase; a rTMS continued treatment phase; and a follow-up.

In order to be enrolled, participants will be screened with:

* Medical history to assess the existence of the inclusion criteria and exclude any medical conditions that could contraindicate treatment with arTMS
* Questionnaires

After being enrolled, baseline data will be collected. In particular, participants will be administered:

* Questionnaires
* Functional MRI
* Cognitive tasks
* Eye examination with Electroretinography (ERG)
* Blood sampling
* Salivary cortisol sampling

Repetitive TMS will be delivered during 5 outpatient treatment days (4 times/die).

After treatment patients will be contacted by telephone on a weekly basis for the first 3 weeks, to carry out an assessment of the clinical condition.

A follow-up visit, in the clinic, will be carried out after 21 days from the last stimulation (Friday), with the administration of psychometric scales.

Blood samples will be taken on the first day of stimulation and the day after the last stimulation.

Salivary cortisol sampling will be taken before the start of the stimulation protocol, after the first stimulation day and immediately after the last stimulation session foreseen by the protocol.

fMRI will be performed during baseline and at the end of treatment. ERG will be performed before the start of the stimulation protocol, after the first stimulation and immediately after the last stimulation session foreseen by the protocol. Patients will undergo ERG again during the follow-up visit at 21 days.

Treatment includes:

* rTMS: A brief electrical current passes through the coil placed on the head. At each day, participants will receive four rTMS sessions (36 min), with a 55 min interval between sessions.
* MRIs: Patients will undergo two MRI sessions lasting 45 min. Blood pressure and respiratory rate will be recorded before the examination. During fMRI, patients will be asked to perform tasks.
* Eye examination with Electroretinography (ERG)
* Blood and salivary sampling.
* Screening tests and questionnaires.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.